Squarepoint
OLMA icon

Squarepoint’s Olema Pharmaceuticals OLMA Stock Holding History

Squarepoint’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-120,000
Closed -$1.79M – 4818
2026
Q1 		$1.79M Buy
+120,000
New +$2.67M ﹤0.01% 2262

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Squarepoint's OLMA Position: Q2 2026 in Review

Squarepoint reduced its Olema Pharmaceuticals (OLMA) stake by 17% in Q2 2026, selling an estimated $1.65M and leaving 615,470 shares worth $7.7M. The position accounts for 0.01% of the portfolio, ranked #1277.

Squarepoint first reported a position in OLMA in Q4 2021 and has held it in 15 quarters since. The position peaked at $11M in Q1 2026. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Squarepoint held 615,470 shares of Olema Pharmaceuticals worth $7.7M as of Q2 2026.
  • Squarepoint sold 123,082 Olema Pharmaceuticals shares in Q2 2026, an estimated $1.65M.
  • Olema Pharmaceuticals made up 0.01% of Squarepoint's portfolio in Q2 2026, its #1277 holding.
  • Squarepoint first reported a position in Olema Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Squarepoint's Olema Pharmaceuticals position peaked at $11M in Q1 2026.
  • 186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.